Argenx
ARGX
#424
Rank
$55.36 B
Marketcap
$889.07
Share price
-1.30%
Change (1 day)
45.51%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): $0.96 Billion USD

According to Argenx 's latest financial reports the company's current earnings are $3.60 Billion USD. In 2024 the company made an earning of $85.18 Million USD, an increase over its 2023 earnings that were of -$0.31 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) $0.96 B1029.16%
2024 $85.18 M-127.97%
2023 -$0.31 Billion-58.25%
2022 -$0.73 Billion
2019 -$0.2 Billion124.86%
2018 -$88.43 Million131.81%
2017 -$38.15 Million54.9%
2016 -$24.63 Million33.71%
2015 -$18.42 Million12.93%
2014 -$16.31 Million46.39%
2013 -$11.15 Million